Cover Image
市場調查報告書

輸卵管癌 : 開發平台分析

Fallopian Tube Cancer - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 229740
出版日期 內容資訊 英文 677 Pages
訂單完成後即時交付
價格
Back to Top
輸卵管癌 : 開發平台分析 Fallopian Tube Cancer - Pipeline Review, H2 2016
出版日期: 2016年10月26日 內容資訊: 英文 677 Pages
簡介

所謂輸卵管癌是指輸卵管──連接卵巢和子宮的管道──所發病的癌症,病例非常稀少。一般的症狀有不正常出血(特別是停經後),及腹部疼痛和壓迫感,異常(白色/透明/粉色的)陰道分泌物,骨盆腔內腫塊等,這些症狀佔患者的2/3。一般是癌細胞由人體其他部位(卵巢、子宮內膜等)轉移到輸卵管造成。卵巢癌的治療方法依年齡及生產意願、腫瘤種類及病期而不同。一般是化療後進行外科手術。

本報告提供全球各國治療輸卵管癌所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

輸卵管癌概要

治療藥的開發

  • 輸卵管癌開發中產品:概要
  • 輸卵管癌開發中產品:比較分析

各企業開發中的輸卵管癌治療藥

大學/研究機關研究中的輸卵管癌治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

輸卵管癌治療藥:開發中的產品一覽(各企業)

輸卵管癌治療藥:研究中的產品一覽(各大學/研究機關)

輸卵管癌治療藥的開發企業

  • AbbVie Inc.
  • Acceleron Pharma, Inc.
  • Adaptimmune Limited
  • Amgen Inc.
  • Array BioPharma Inc.
  • Astex Pharmaceuticals, Inc.
  • AstraZeneca Plc
  • Atara Biotherapeutics, Inc.
  • Bayer AG
  • BioMarin Pharmaceutical Inc.
  • Bionomics Limited
  • Boehringer Ingelheim GmbH
  • Caladrius Biosciences, Inc.
  • Celldex Therapeutics, Inc.
  • Celsion Corporation
  • Cerulean Pharma, Inc.
  • Clovis Oncology, Inc.
  • Corcept Therapeutics Incorporated
  • Critical Outcome Technologies Inc.
  • CTI BioPharma Corp.
  • Curis, Inc.
  • Dr. Reddy's Laboratories Limited
  • EirGenix Inc.
  • Eli Lilly and Company
  • Epirus Biopharmaceuticals, Inc.
  • Exelixis, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Galena Biopharma, Inc.
  • Genentech, Inc.
  • Genor BioPharma Co., Ltd.
  • GlaxoSmithKline Plc
  • Glycotope GmbH
  • Gradalis Inc.
  • Hetero Drugs Limited
  • Immune Design Corp.
  • ImmunoGen, Inc.
  • Immunotope, Inc.
  • Immunovaccine, Inc.
  • Incyte Corporation
  • Innate Pharma SA
  • Johnson & Johnson
  • Karyopharm Therapeutics, Inc.
  • Kyowa Hakko Kirin
  • Lee's Pharmaceutical Holdings Limited
  • MabVax Therapeutics Holdings, Inc.
  • MedImmune, LLC
  • Merck & Co., Inc.
  • Merrimack Pharmaceuticals, Inc.
  • Millennium Pharmaceuticals, Inc.
  • Novartis AG
  • Oasmia Pharmaceutical AB
  • OBI Pharma, Inc.
  • Oncobiologics, Inc.
  • Oncolytics Biotech Inc.
  • OncoMed Pharmaceuticals, Inc.
  • Onxeo SA
  • Oxford BioMedica Plc
  • OXiGENE, Inc.
  • Pharma Mar, S.A.
  • Pharmacyclics, Inc.
  • PsiOxus Therapeutics Limited
  • Recepta Biopharma S.A.
  • Sanofi Pasteur SA
  • Synta Pharmaceuticals Corp.
  • TapImmune Inc.
  • Tesaro, Inc.
  • TetraLogic Pharmaceuticals
  • Vascular Biogenics Ltd.
  • VentiRx Pharmaceuticals, Inc.

輸卵管癌:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • (ID-LV305 + ID-G305)
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • abexinostat hydrochloride
  • abiraterone acetate
  • ABT-767
  • afuresertib hydrochloride
  • alisertib
  • anetumab ravtansine
  • AZD-1775
  • AZD-2014
  • AZD-5363
  • belinostat
  • Bevacizumab
  • Bevacizumab的生技仿製藥
  • binimetinib
  • birinapant
  • BNC-105 1
  • cabozantinib s-malate
  • 癌症幹細胞療法
  • 癌症疫苗
  • CDX-1401
  • CD3·HER2標的細胞療法
  • NY-ESO-1標的細胞療法
  • WT1標的細胞療法
  • COTI-2
  • CRLX-101
  • CUDC-427
  • dalantercept
  • demcizumab
  • 卵巢·腹膜·輸卵管癌樹書細胞療法
  • DMUC-4064A
  • DPX-Survivac
  • EGEN-001
  • elesclomol
  • enadenotucirev
  • epacadostat
  • erismodegib
  • fosbretabulin tromethamine
  • GALE-301
  • ganetespib
  • 適合腫瘤學p53活躍基因治療
  • gimatecan
  • guadecitabine
  • IMT-1012
  • ipafricept
  • IPH-2201
  • LCL-161
  • lifastuzumab vedotin
  • lurbinectedin
  • mifepristone
  • mirvetuximab soravtansine
  • MK-2206
  • motolimod
  • nintedanib
  • niraparib
  • NSC-748933
  • OBI-822/821
  • olaratumab
  • paclitaxel
  • paclitaxel poliglumex
  • PankoMab-GEX
  • pazopanib hydrochloride
  • pelareorep
  • pembrolizumab
  • prexasertib
  • ralimetinib mesylate
  • ramucirumab
  • RebmAb-100
  • regorafenib
  • rucaparib phosphate
  • selinexor
  • seribantumab
  • talazoparib
  • tivozanib
  • TPIV-200
  • trabectedin
  • trebananib
  • tremelimumab
  • TroVax
  • 腫瘤學疫苗
  • varlilumab
  • VB-111
  • vCP-2292
  • veliparib
  • X-82

輸卵管癌治療藥:開發中產品的最新趨勢

輸卵管癌治療藥:開發暫停的產品

輸卵管癌治療藥:開發中止的產品

輸卵管癌相關產品的開發的里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8595IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fallopian Tube Cancer - Pipeline Review, H2 2016, provides an overview of the Fallopian Tube Cancer (Oncology) pipeline landscape.

Fallopian tube cancer is also called tubal cancer. It develops in the fallopian tubes, which serve as a connection between the ovaries and the uterus. It occurs very rarely. The common symptoms of fallopian tube cancer may include abnormal vaginal bleeding, especially after menopause, abdominal pain or a feeling of pressure in the abdomen, abnormal vaginal discharge that is white, clear or pinkish and a pelvic mass at the time of diagnosis, which is present in up to two-thirds of patients. Usually, cancer metastasizes from other parts of the body such as the ovaries or endometrium to the fallopian tubes. Fallopian tube cancer treatment depends on age, the desire to have children, type and stage of the tumor. It usually involves surgery followed by chemotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Fallopian Tube Cancer - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Fallopian Tube Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Fallopian Tube Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Fallopian Tube Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Unknown stages are 1, 2, 12, 51, 25, 1, 1, 8 and 1 respectively for Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 3 and 1 molecules, respectively for Fallopian Tube Cancer.

Fallopian Tube Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Fallopian Tube Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Fallopian Tube Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Fallopian Tube Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Fallopian Tube Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Fallopian Tube Cancer (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Fallopian Tube Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Fallopian Tube Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Fallopian Tube Cancer Overview
  • Therapeutics Development
  • Fallopian Tube Cancer - Therapeutics under Development by Companies
  • Fallopian Tube Cancer - Therapeutics under Investigation by Universities/Institutes
  • Fallopian Tube Cancer - Pipeline Products Glance
  • Fallopian Tube Cancer - Products under Development by Companies
  • Fallopian Tube Cancer - Products under Investigation by Universities/Institutes
  • Fallopian Tube Cancer - Companies Involved in Therapeutics Development
  • Fallopian Tube Cancer - Therapeutics Assessment
  • Drug Profiles
  • Fallopian Tube Cancer - Discontinued Products
  • Fallopian Tube Cancer - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Fallopian Tube Cancer, H2 2016
  • Number of Products under Development for Fallopian Tube Cancer - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Development by Companies, H2 2016 (Contd..3)
  • Number of Products under Development by Companies, H2 2016 (Contd..4)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Development by Companies, H2 2016 (Contd..5)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Fallopian Tube Cancer - Pipeline by AbbVie Inc, H2 2016
  • Fallopian Tube Cancer - Pipeline by Acetylon Pharmaceuticals, Inc., H2 2016
  • Fallopian Tube Cancer - Pipeline by Adaptimmune Therapeutics Plc, H2 2016
  • Fallopian Tube Cancer - Pipeline by Aduro BioTech, Inc., H2 2016
  • Fallopian Tube Cancer - Pipeline by Advenchen Laboratories, LLC, H2 2016
  • Fallopian Tube Cancer - Pipeline by Amgen Inc., H2 2016
  • Fallopian Tube Cancer - Pipeline by Astex Pharmaceuticals, Inc., H2 2016
  • Fallopian Tube Cancer - Pipeline by AstraZeneca Plc, H2 2016
  • Fallopian Tube Cancer - Pipeline by Atara Biotherapeutics, Inc., H2 2016
  • Fallopian Tube Cancer - Pipeline by Bayer AG, H2 2016
  • Fallopian Tube Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Fallopian Tube Cancer - Pipeline by Boston Biomedical, Inc., H2 2016
  • Fallopian Tube Cancer - Pipeline by Celldex Therapeutics, Inc., H2 2016
  • Fallopian Tube Cancer - Pipeline by Celsion Corporation, H2 2016
  • Fallopian Tube Cancer - Pipeline by Cerulean Pharma, Inc., H2 2016
  • Fallopian Tube Cancer - Pipeline by Clovis Oncology, Inc., H2 2016
  • Fallopian Tube Cancer - Pipeline by Critical Outcome Technologies Inc., H2 2016
  • Fallopian Tube Cancer - Pipeline by CTI BioPharma Corp., H2 2016
  • Fallopian Tube Cancer - Pipeline by Dr. Reddy's Laboratories Limited, H2 2016
  • Fallopian Tube Cancer - Pipeline by EirGenix Inc., H2 2016
  • Fallopian Tube Cancer - Pipeline by Eisai Co., Ltd., H2 2016
  • Fallopian Tube Cancer - Pipeline by Eli Lilly and Company, H2 2016
  • Fallopian Tube Cancer - Pipeline by Esperance Pharmaceuticals, Inc., H2 2016
  • Fallopian Tube Cancer - Pipeline by Exelixis, Inc., H2 2016
  • Fallopian Tube Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Fallopian Tube Cancer - Pipeline by Galena Biopharma, Inc., H2 2016
  • Fallopian Tube Cancer - Pipeline by Ganymed Pharmaceuticals AG, H2 2016
  • Fallopian Tube Cancer - Pipeline by Gene Techno Science Co., Ltd., H2 2016
  • Fallopian Tube Cancer - Pipeline by Genentech, Inc., H2 2016
  • Fallopian Tube Cancer - Pipeline by Genor BioPharma Co Ltd, H2 2016
  • Fallopian Tube Cancer - Pipeline by Glycotope GmbH, H2 2016
  • Fallopian Tube Cancer - Pipeline by Gradalis Inc., H2 2016
  • Fallopian Tube Cancer - Pipeline by Ignyta, Inc., H2 2016
  • Fallopian Tube Cancer - Pipeline by Immune Design Corp., H2 2016
  • Fallopian Tube Cancer - Pipeline by ImmunoGen, Inc., H2 2016
  • Fallopian Tube Cancer - Pipeline by Immunovaccine, Inc., H2 2016
  • Fallopian Tube Cancer - Pipeline by Incyte Corporation, H2 2016
  • Fallopian Tube Cancer - Pipeline by Innate Pharma S.A., H2 2016
  • Fallopian Tube Cancer - Pipeline by Johnson & Johnson, H2 2016
  • Fallopian Tube Cancer - Pipeline by Juno Therapeutics Inc., H2 2016
  • Fallopian Tube Cancer - Pipeline by Karyopharm Therapeutics, Inc., H2 2016
  • Fallopian Tube Cancer - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2016
  • Fallopian Tube Cancer - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2016
  • Fallopian Tube Cancer - Pipeline by Mabion SA, H2 2016
  • Fallopian Tube Cancer - Pipeline by MabVax Therapeutics Holdings, Inc., H2 2016
  • Fallopian Tube Cancer - Pipeline by Mateon Therapeutics Inc, H2 2016
  • Fallopian Tube Cancer - Pipeline by MedImmune, LLC, H2 2016
  • Fallopian Tube Cancer - Pipeline by Medivation, Inc., H2 2016
  • Fallopian Tube Cancer - Pipeline by Merck & Co., Inc., H2 2016
  • Fallopian Tube Cancer - Pipeline by Merck KGaA, H2 2016
  • Fallopian Tube Cancer - Pipeline by Millennium Pharmaceuticals Inc, H2 2016
  • Fallopian Tube Cancer - Pipeline by MolMed S.p.A., H2 2016
  • Fallopian Tube Cancer - Pipeline by Mycenax Biotech Inc., H2 2016
  • Fallopian Tube Cancer - Pipeline by Novartis AG, H2 2016
  • Fallopian Tube Cancer - Pipeline by OBI Pharma, Inc., H2 2016
  • Fallopian Tube Cancer - Pipeline by Oncobiologics, Inc., H2 2016
  • Fallopian Tube Cancer - Pipeline by Oncolix, Inc., H2 2016
  • Fallopian Tube Cancer - Pipeline by Oncolytics Biotech Inc., H2 2016
  • Fallopian Tube Cancer - Pipeline by OncoMed Pharmaceuticals, Inc., H2 2016
  • Fallopian Tube Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016
  • Fallopian Tube Cancer - Pipeline by Oxford BioMedica Plc, H2 2016
  • Fallopian Tube Cancer - Pipeline by Pharma Mar, S.A., H2 2016
  • Fallopian Tube Cancer - Pipeline by PsiOxus Therapeutics Limited, H2 2016
  • Fallopian Tube Cancer - Pipeline by Quest PharmaTech Inc., H2 2016
  • Fallopian Tube Cancer - Pipeline by Richter Gedeon Nyrt., H2 2016
  • Fallopian Tube Cancer - Pipeline by Samyang Holdings Corporation, H2 2016
  • Fallopian Tube Cancer - Pipeline by Sanofi Pasteur SA, H2 2016
  • Fallopian Tube Cancer - Pipeline by Sellas Inc, H2 2016
  • Fallopian Tube Cancer - Pipeline by Shenzen SiBiono GeneTech Co., Ltd., H2 2016
  • Fallopian Tube Cancer - Pipeline by Sotio a.s., H2 2016
  • Fallopian Tube Cancer - Pipeline by TapImmune Inc., H2 2016
  • Fallopian Tube Cancer - Pipeline by Tara Immuno-Oncology Therapeutics LLC, H2 2016
  • Fallopian Tube Cancer - Pipeline by Tesaro, Inc., H2 2016
  • Fallopian Tube Cancer - Pipeline by TetraLogic Pharmaceuticals, H2 2016
  • Fallopian Tube Cancer - Pipeline by Tyrogenex, Inc., H2 2016
  • Fallopian Tube Cancer - Pipeline by Vascular Biogenics Ltd., H2 2016
  • Fallopian Tube Cancer - Pipeline by VentiRx Pharmaceuticals, Inc., H2 2016
  • Fallopian Tube Cancer - Pipeline by Vyriad Inc, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Fallopian Tube Cancer - Dormant Projects, H2 2016
  • Fallopian Tube Cancer - Dormant Projects (Contd..1), H2 2016
  • Fallopian Tube Cancer - Dormant Projects (Contd..2), H2 2016
  • Fallopian Tube Cancer - Dormant Projects (Contd..3), H2 2016
  • Fallopian Tube Cancer - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Fallopian Tube Cancer, H2 2016
  • Number of Products under Development for Fallopian Tube Cancer - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Top 10 Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top